OrthoPediatrics (NASDAQ:KIDS) Upgraded at TD Cowen

TD Cowen upgraded shares of OrthoPediatrics (NASDAQ:KIDS) to a strong-buy rating in a research report report published on Tuesday,Zacks.com reports.

Other research analysts have also issued reports about the stock. Stifel Nicolaus cut their price objective on shares of OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, October 10th. Truist Financial set a $18.00 price target on shares of OrthoPediatrics in a research report on Friday, October 10th. Piper Sandler cut their price target on shares of OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Canaccord Genuity Group initiated coverage on shares of OrthoPediatrics in a report on Wednesday, December 10th. They issued a “buy” rating and a $24.00 price target on the stock. Finally, Needham & Company LLC dropped their price objective on OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $23.89.

OrthoPediatrics Trading Down 0.2%

Shares of OrthoPediatrics stock opened at $17.29 on Tuesday. OrthoPediatrics has a fifty-two week low of $15.28 and a fifty-two week high of $26.40. The business’s fifty day moving average is $18.09 and its two-hundred day moving average is $18.78. The company has a quick ratio of 3.52, a current ratio of 7.40 and a debt-to-equity ratio of 0.28. The firm has a market cap of $433.63 million, a PE ratio of -8.87 and a beta of 1.09.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. OrthoPediatrics had a negative return on equity of 6.86% and a negative net margin of 20.06%.The business had revenue of $61.25 million during the quarter, compared to the consensus estimate of $63.63 million. Analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current year.

Hedge Funds Weigh In On OrthoPediatrics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its position in OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the period. Caption Management LLC acquired a new position in shares of OrthoPediatrics during the third quarter worth about $54,000. BNP Paribas Financial Markets lifted its stake in shares of OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of OrthoPediatrics in the second quarter worth about $220,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after buying an additional 645 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.